Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis

Open Access

Peer-reviewed

Research Article

Diego Cadavid ,

* E-mail: diego.cadavid@biogenidec.com

Affiliation MS Clinical Development Group, Biogen Idec, Cambridge, Massachusetts, United States of America
⨯
Stephanie Jurgensen,

Affiliation MS Global Medical Affairs, Genzyme, a Sanofi Company, Cambridge, Massachusetts, United States of America
⨯
Sophia Lee

Affiliation Biometrics, Biogen Idec, Cambridge, Massachusetts, United States of America
⨯

Reader Comments (0)

Walking
Is the Subject Area "Walking" applicable to this article?

Thanks for your feedback.
Multiple sclerosis
Is the Subject Area "Multiple sclerosis" applicable to this article?

Thanks for your feedback.
Phase III clinical investigation
Is the Subject Area "Phase III clinical investigation" applicable to this article?

Thanks for your feedback.
Interferons
Is the Subject Area "Interferons" applicable to this article?

Thanks for your feedback.
Cognitive impairment
Is the Subject Area "Cognitive impairment" applicable to this article?

Thanks for your feedback.
Lesions
Is the Subject Area "Lesions" applicable to this article?

Thanks for your feedback.
Phase II clinical investigation
Is the Subject Area "Phase II clinical investigation" applicable to this article?

Thanks for your feedback.
Quality of life
Is the Subject Area "Quality of life" applicable to this article?

Thanks for your feedback.